In a family who expressed severe dominantly inherited osteoarthritis, the underlying mutation was traced by genomic sequencing to a single base change which predicts an amino acid substitution of cysteine for arginine at residue 519 of the triple-helical domain of the type II collagen molecule (AlaKokko, L., C. T. Baldwin, R. W. Moskowitz, and D. J. . Proc. NatL Acad. Sci. USA. 87:6565-6568). In the present study we examined whether this predicted protein phenotype was evident in articular cartilage obtained from an affected family member who underwent hip surgery. The cartilage collagen was solubilized by CNBr digestion. Cysteine residues were labeled by reduction and alkylation with 14C-iodoacetate. Collagen CNBr-peptides were fractionated by ion exchange and reverse phase column chromatography. One peptide from the al(II) chain, al(II) CB8, was found to be radiolabeled. Tryptic peptides were prepared from it and identified by microsequence analysis. The results show that approximately one-quarter of the al(II) chains present in the polymeric extracellular collagen of the patient's cartilage contained the Ar&g19-to-Cys substitution. The protein exhibited other abnormal properties including disulfide-bonded al(II)-dimers and signs of posttranslational overmodification. The premature cartilage failure and osteoarthritis are presumably a result of the abnormal type II collagen being expressed in the cartilage matrix. (J. Clin. Invest. 1991. 87:357-361.)
Introduction
Osteoarthritis (OA)' is the most common disease ofjoints.
Though of diverse etiology and poorly understood pathogenesis, its cardinal feature is a progressive disruption and erosion of articular cartilage (1) . Articular cartilage consists mostly of an extracellular matrix that is essentially a collagen fibril network filled with highly hydrated proteoglycans (2) . The collagen network is a covalent polymer oftype II collagen molecules (each molecule a homotrimer, [a (I1)]3, that normally lacks any cysteine residues), in association with two other cartilagespecific collagens, types IX and XI, in small amounts (3) . In adult cartilage, chondrocytes continue to synthesize and replace proteoglycans but turn over the collagen slowly (4) so that most of its fabric must function for life.
Various forms of familial generalized OA have been described (5, 6) . In three unrelated families who expressed severe dominantly inherited osteoarthritis, linkage studies showed that the condition was coinherited with an allele ofthe collagen type II gene (COL2A 1) (7, 8) . The patient in the present study, G.J. (age 46 at time of left total hip replacement), and other affected family members experienced joint symptoms in their second and third decades, which progressed into typical clinical and radiographic evidence of generalized OA (8, 9) . Although the affected family members had mild spinal chondrodysplasia, their precocious OA developed in peripheral joints that lacked epiphyseal deformities or other evidence ofchondrodysplasia. The recent demonstration that the dominantly inherited disease symptoms were cotransmitted with a mutant COL2A1 allele that predicts an Arg5l9-to-Cys substitution (10) implies that the disease is a direct result of abnormally expressed type II collagen in joint cartilage. With the availability of surgical tissue, this prediction was tested by protein analysis of the collagen from the cartilage matrix. The results confirm the expression of the mutant protein and imply that the osteoarthritis is a consequence ofthe collagen molecular abnormality in the cartilage.
Methods
Articular cartilage was sampled from relatively intact surfaces on the surgically removed femoral head and stored frozen at -70'C. Areas of severe erosion and potential fibrocartilaginous repair were avoided.
Preparation and chromatography ofCNBr-peptides and trypticpeptides. A portion ofcartilage (40 mg dry wt) from the least pathologically involved surfaces on the femoral head was digested with CNBr in 70% (vol/vol) formic acid (I 1). The digest was reduced with dithiothreitol and alkylated with '4C-iodoacetic acid to convert cysteines to '4C-carboxymethylcysteine (12) and so provide a marker for the mutant peptide. Collagen CNBr-peptides were fractionated by sequential cationexchange (Mono-S HR 5/5; Pharmacia Fine Chemicals, Piscataway, NJ) and reverse phase (C8, 25 cm X 4.6 mm, model RP-300; Brownlee Labs, Santa Clara, CA) HPLC (13, 14) . Fractions encompassing '4C-labeled and unlabeled al(II)CB8 (identified by liquid scintillation counting and SDS-PAGE), were pooled and digested with trypsin (sequenc-ing grade; Boehringer Mannheim Biochemicals, Indianapolis, IN). Tryptic peptides were separated by reverse phase HPLC (Brownlee Labs RP-300) using a gradient (0-30% in 60 min) ofacetonitrile: n-propanol (3:1 vol/vol) in 0.1% (vol/vol) of trifluoracetic acid at 1 ml/min (14) . Peptide yields were compared by the areas under their UV absorbance peaks and the recoveries of PTH-amino acids on sequence analysis.
Pepsin-solubilized collagen. Another portion (40 mg dry wt) of the finely diced tissue from the most intact surfaces on the femoral head was extracted in 4 M guanidine HCI, 0.05 M Tris/HCI, pH 7.0 at 40C for 48 h. The washed residue was digested with pepsin and solubilized collagen type II molecules were isolated by differential precipitation with NaCi as described (15) . Collagen from normal human articular cartilage from a male, age 25, was prepared similarly as a control. A portion ofthe patient's isolated type II collagen was reduced and alkylated with '4C-iodoacetate. SDS-PAGE was carried out by the method of Laemmli (16) in 6 and 12.5% polyacrylamide gels.
Protein microsequencing. Edman sequencing of individual tryptic peptides was carried out on a Porton 2090E machine equipped with on-line HPLC analysis ofphenylthiohydantoin PTH amino acids using the manufacturer's standard program.
Results
The '4C-iodoacetate-treated CNBr-digest of the patient's cartilage gave one major '4C-labeled component on cation exchange HPLC (Fig. I a) . The fractions marked by the bar were shown by SDS-PAGE to encompass the peptide al(II)CB8, and were pooled for reverse phase HPLC (Fig. 1 b) . Similarly, the pool of further purified al(II)CB8 (indicated by bar in Fig.  1 b) was dried for trypsin digestion. The columns used for the chromatograms in Fig. 1 , a and b, were calibrated with type II collagen CNBr-peptides from normal human cartilage. In Fig. I a, the peak eluting between fractions 25 and 35 is al(II)CB1O and between fractions 40 and 50 is al(II)CBl 1; radiolabeled a 1 (II)CB8 eluted slightly earlier than unlabeled a I (II)CB8, hence the broad pool of fractions taken for further analysis. tient's cartilage. It can be seen that the mutant a l(II)CB8S peptide is slightly retarded on SDS-PAGE compared with its unlabeled normal counterpart, which could be a result of it being more overmodified posttranslationally or an effect of the carboxymethylcysteine residue replacing arginine. Tryptic peptides from the al(II)CB8 fragment were fractionated by reverse-phase HPLC (Fig. 3) . The 14C activity was recovered in a single peptide, T4,6 (Fig. 3 a) . This peptide, and several of the other tryptic fragments (T1-T7) of al(II)CB8 indicated as peaks in Fig. 3 b, were identified by aminoterminal microsequencing. Fig. 3 a is more complex than Fig. 3 b because the CNBr-peptide fraction from the patient taken for trypsin digestion (see Fig. 1 ) was less pure than the control, to ensure a quantitative recovery of the total pool of mutant and normal al(II)CB8. The small peak of 14C-activity eluting at 41 min in Fig. 3 a appears to be a chromatographic variant ofT4,6 since microsequencing gave the T4,6 sequence including 14C-carboxymethylcysteine at cycle 12; the two peaks may represent homoserine and homoserine lactone-containing forms of the peptide ( 17). Fig. 4 compares the results of microsequence analysis on peptide T4,6 with the known sequence of human al(II)CB8, and shows the identification of '4C-carboxymethylcysteine at cycle 12 (residue 519 of the human al(11) triple helical domain). In all, sequencing identified the first 42 amino acids of the 44-residue T4,6 peptide, identical to the cDNA-based sequence shown in Fig. 4 b except for Cys519. The yields of peptides T4 and T6 (which derive from the product ofthe patient's normal allele) relative to peptide T4,6 and to other peptides common to both alleles, indicated a ratio of mutant to normal al(II) chains in the patient's tissue of 1:3. Collagen extracted from the patient's cartilage by pepsin showed a protein band by SDS-PAGE that was absent from extracts of control human cartilage and which disappeared after disulfide cleavage (Fig. 5 a, lanes I and 3) . We believe this to be an abnormal a I(H1)-dimer from type II collagen molecules in which two mutant al(II) chains became disulfide bonded through their Cys519 residues. The mobility of the patient's a 1(I) chain was slightly slower than that of the control human a1(H1) chain (Fig. 5 a) . Both a 1(11) and the normal ,B component of the pepsin-solubilized type II collagen were radiolabeled by '4C-iodoacetate in proportion to their relative staining by Coomassie blue. This suggests that the cysteinecontaining a 1(I) chain was cross-linked by the aldehyde mechanism normally in the extracellular matrix. The major CNBr-peptides from the patient's type II collagen also ran more slowly than their counterparts from control cartilage (Fig. 5 b) , which suggests from past experience a degree ofposttranslational overmodification (18) . Peptides CB1O and CB 1 1, which lie respectively COOH-terminal and NH2-terminal to the peptide a 1(II)CB8 containing the mutation (19), were both affected. In contrast, amino acid substitutions for 4) (20) . Because during synthesis the direction of helix formation is believed to be in the COOH-to-NH2 direction, these mutations are believed to hinder helix folding and so cause overmodification of the chains from the mutation site to the aminoterminus. In the present case, however, the cysteine is substituted for a Y position of the collagen (GXY). repeating sequence, which might affect triple-helix formation and molecular assembly differently than substitutions for glycine.
Discussion
The genomic mutation identified by Ala-Kokko et al. (10) shown). This evidence for normal cross-linking and the insolubility of the patient's cartilage collagen in denaturing solvents lead us to conclude that collagen molecules containing the mutant a 1(II) chains were incorporated and covalently polymerized into extracellular fibrils. The content of mutant a 1(II) chains in the extracellular type II collagen was lower than the theoretical 50% for a dominant heterozygote; this might be explained if some molecules bearing mutant chains were selectively degraded at or soon after synthesis. Certain chain combinations may be more susceptible to degradation. (In theory for a homotrimer, seven-eighths ofthe molecules will contain mutant chains, one-eighth containing three, two-eighths containing two, and four-eighths containing one mutant chain: oneeighth molecules will be normal.) Other mutations of the human COL2A1 gene have been defined that have serious consequences, causing lethal or severe skeletal abnormalities in the clinical spectrum of the spondyloepiphyseal dysplasias (22) (23) (24) .
We postulate that the presence ofthe mutant protein molecules in the extracellular collagen reduces the durability of the articular cartilage and manifests as the disorder, severe primary generalized OA. The fibrils may be less able in the long term to cope with the mechanical stresses that articular cartilage endures, perhaps through defects in material properties. In addition the collagen may be more susceptible to extracellular proteases that are active in matrix remodeling but which do not normally degrade the collagen triple-helix (25). The cysteine residue conceivably might serve as a covalent trap for matrix proteins that associate with the surface of collagen fibrils (26) , with undesirable consequences. Because failure ofthe underlying collagen fabric of cartilage appears to be a key, irreversible event in the process ofjoint destruction in OA in all its subsets (27) , defining how this single amino acid substitution is etiologically associated with severe but otherwise typical disease manifestations may prove instructive in understanding osteoarthritic joint failure.
